According to Actoverco pharmaceutical Group; Trytis is going to be launched and released on the market soon. Trytis is an oral combination diabetes medication used to control blood sugar in people with type 2 diabetes. This drug is a combination of metformin, empagliflozin and linagliptin, which reduces blood sugar with three different mechanisms.
Approximately 11% of Iran’s population over 20 years of age suffer from diabetes, and nearly half of them are not aware of their disease.
Nowadays, usage of combined drugs with the lowest number of pills are taken per day and with high effectiveness, has created a great evolution in the control of diabetes and leads to successful treatment. Empagliflozin in this pill is associated with a reduction in mortality due to the complications of cardiovascular diseases, heart failure or diabetic kidney diseases. Taking this drug in diabetics can reduce the risk of problems which are related to cardiovascular and kidney failure.
Earlier, Actoverco pharmaceutical Group was able to help in the treatment of diabetes in the country by producing medicines such as Dipeta plus®, Dipeta®, Empaver, Empaver plus, Glicover, Glodap®, Glodaplus®, Glucovance, Glypover®, Glysta and Sigomet. For more information, refer to this diabetes link.
Trytis drug has been produced with the latest technology via Actoverco Pharmaceutical Group and will be available to diabetic patients by the end of May 2024.
